Abstract

Gut microbes can shape cancer immunotherapy responses; however, specific taxa have not been tested prospectively as biomarkers. Derosa and colleagues now demonstrate that the presence of Akkermansia muciniphila in baseline stool samples can be associated with improved outcomes and enhanced antitumor immune cell infiltrates in patients with lung cancer treated with immune checkpoint blockade (ICB).

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call